【纠错】 【责任编辑:薛涛】 农产品贸易规模扩大。2025年前11个月，中韩进出口农产品521.9亿元，同比增长2.1%。其中，中国自 韩国进口酒类及饮料、面食产品，对韩国出口干鲜瓜果及坚果、茶叶同比增速均达到两位数。 新华社北京1月4日电（记者邹多为）海关总署1月4日发布数据显示，2025年前11个月，中国与韩国进出 口2.14万亿元，同比增长1.6%，其中，进出口机电产品1.43万亿元，增长5.9%，占中韩贸易规模的 67%，较上年同期提升2.7个百分点，成为推动中韩贸易平稳增长的重要动力。 具体来看，2025年前11个月，中国自韩国进口1.2万亿元，对韩国出口0.94万亿元，中韩贸易占中国外贸 的5.2%。 产业链供应链协同合作深化。2025年前11个月，中国自韩国进口电子元件、电脑零附件同比分别增长 9.9%、7.4%；对韩国出口电子元件、汽车零配件分别增长10%、8.9%。 新兴领域合作潜力释放。2025年前11个月，中国自韩国进口医药材及药品、电工器材同比分别增长 8.9%、3%；对韩国出口"新三样"产品、医疗仪器及器械分别增长12.4%、1.1%。 ...

贸易政策与产业、供应链联系得更紧密。报告指出，在报告期内，各国政府对农业、环境与能源等领域 实施的支持性政策显著增加，尤其是非金融支持措施大幅增长。在环境与能源领域，各国采取的政策措 施包括制定新的排放标准、安全标准、能耗要求，调整公共采购偏好，以优先购买低碳、环境友好型与 新能源产品，进行配额和许可制度改革以推动清洁能源结构调整，制定鼓励技术发展与本地化要求相关 政策以促进可再生能源装备本地生产等。在农业领域，各国出台的相关措施在报告期内显著增加，涵盖 国内支持、市场准入措施、卫生与植物检疫措施更新、出口相关措施等方面。农业政策高度关联食品安 全、供应链稳定与可持续发展目标，各国大量出台有关措施保证粮食供应安全、应对气候变化、增加本 国产能、减少进口依赖，折射出贸易政策与产业政策的高度关联。报告还注意到，许多新增产业政策措 施并非传统补贴的形式，而是通过非金融方式对特定产业给予支持，说明各国政府正在强化对关键领域 的干预和引导。世贸组织认为，有关产业政策会从国际竞争条件、价值链布局、市场准入条件等方面对 全球贸易产生结构性影响。随着全球市场干预度普遍提升，未来可能带来贸易扭曲风险、支持政策之间 的竞争性累积 ...

不过，全球贸易活动和世贸规则体系仍有韧性。报告指出，尽管2024年至2025年全球贸易环境高度紧 张，关税等贸易限制措施急剧加码，但全球贸易活动保持比预期更强的增长，多边贸易体系依然是世界 贸易的主要制度基础。报告将2025年全球货物贸易增长预测从0.9%上调至2.4%，并指出贸易活动能在 地缘政治紧张和关税累积背景下保持增长，反映出贸易需求更强，具有超出预期的韧性。报告指出，人 工智能相关产品强劲拉动全球贸易，其贸易额虽然只占全球贸易的不到六分之一，但贡献了近一半的全 球贸易增长。同时，基于世贸组织规则的多边贸易体系也展现出较强韧性，据统计，当前72%的全球货 物贸易仍在最惠国待遇规则下进行，证明了尽管单边措施频发，但大部分贸易仍依赖多边规则体系支 撑。 报告对未来贸易前景给出了较为谨慎的判断，指出中期全球贸易将因地缘政治与不确定性而放缓，尤其 是主要区域增速将放缓，全球经济前景风险上升。根据世贸组织模型预测，2026年多国将持续出台贸易 限制与保护措施，全球需求承压，货物贸易增速将比2025年有所回落。针对这一下行压力，报告呼吁各 国加强相互合作并推动有关改革，以应对当前更具风险的贸易环境。报告建议各国以 ...

Core Viewpoint - The digital PCR market in China is experiencing intense competition, with three leading brands: Bio-Rad, QIAGEN, and Xinyi, following Bio-Rad's acquisition of Stilla, which significantly increased its market share in the research sector [1][24]. Market Overview - The digital PCR market is characterized by a diverse landscape, with domestic brands accounting for a significant portion of the market share in terms of units sold, while imported brands maintain a revenue advantage due to higher pricing [3][5]. - In terms of bid amounts, imported brands hold a 48.91% share, while domestic brands account for 40.45%, with the remainder attributed to unknown brands [5]. - Domestic brands have captured 50% of the total units sold, indicating a trend towards "domestic substitution," driven by cost-effectiveness and localized service advantages [7]. Procurement Analysis - The primary demand for digital PCR technology comes from academic institutions and hospitals, which are the core procurement entities [8][12]. - The top three procurement entities by bid amount are universities (35.97%), hospitals (27.66%), and research institutes (13.18%), collectively representing over 74% of the market [10][12]. Brand Competition - Bio-Rad leads the market with a bid amount share of 24.51%, followed by QIAGEN at 19.91% and Xinyi at 16.74% [14]. - In terms of units sold, Xinyi leads with a 19.23% share, followed by Bio-Rad at 16.35% and QIAGEN at 15.38% [17]. - Following the acquisition of Stilla, Bio-Rad's overall market share is expected to increase, with a projected unit bid share of 20.19% and a revenue share of 28.24% [17]. Research Market Insights - The research sector is the largest application market for digital PCR, with Bio-Rad, QIAGEN, and Xinyi occupying the top three positions in bid amounts [21]. - In the research market, Bio-Rad holds a 29.43% share, QIAGEN 21.10%, and Xinyi 15.85%, indicating strong brand loyalty and demand for high-performance instruments [21]. - After including Stilla's data, Bio-Rad's share in the research sector could rise to 33.92% in bid amounts and 25.45% in units sold, reinforcing its dominance [23]. Summary and Outlook - The digital PCR market from January to October 2025 illustrates a scenario of "imported leadership, domestic rise, and diversified competition" [24]. - Bio-Rad remains a market leader in the high-end research sector, while domestic brands are becoming mainstream through competitive pricing strategies [24]. - Future growth in the digital PCR market is anticipated due to advancements in molecular diagnostics, expanded clinical applications, and sustained research funding, with competition extending beyond hardware to include reagents, consumables, software analysis, and comprehensive solutions [24].

摘要 ： 2025年1-10月国内数字PCR市场呈现白热化竞争态势。市场呈现伯乐、凯杰、新羿三大品牌引 领的多元格局。值得关注的是，伯乐在完成对Stilla的并购后，其整体与科研市场份额显著提升。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2 0 2 5年，在精准医疗、病原检测和生命科学研究持续深入的背景下，数字PCR作为高灵敏度、 绝对定量的核酸检测技术，其市场需求保持稳定增长。 仪器信息网对2 0 2 5年1 - 1 0月公开 中标数据进行了统计分析 （总中标金额约为1 . 3亿元），从 品牌竞争、采购主体、应用领域等多维度解读当前数字PCR市场格局与发展趋势。 总体市场格局：国产台数占半壁江山，进口品牌仍占金额优势 本 次 中 标 盘 点 共 统 计 到 6 家 进 口 品 牌 ： 伯 乐 （ Bio-Rad ） 、 凯 杰 （ QIAGEN ） 、 罗 氏 （ Roche ） 、 赛 默 飞 （ Thermo Fi sheries ） 、 Sti l la 、 锐 讯 （ RainSure ） 和 10 家 国 产 品 牌： ...

Core Viewpoint - BD (Becton, Dickinson and Company) has officially launched the new BD FACSDi scover™ A8 imaging spectral flow cytometer series, which includes three-laser and four-laser configurations, complementing the previously released five-laser instruments, thereby providing more scientists with access to leading-edge technology in various fields such as immunology, cancer immunotherapy, and cell biology [1][2]. Group 1 - The BD FACSDi scover™ A8 series is equipped with BD SpectralFX™ technology, allowing scientists to analyze up to 50 or more features of individual cells with optimal resolution and sensitivity [2]. - The series also features BD CellView™ imaging technology, enabling high-speed imaging to reveal spatial and morphological information of cells, such as the location of proteins within individual cells, which can be visualized in real-time [2]. - All configurations of the BD FACSDi scover™ A8 series offer high throughput and unattended automation capabilities, optimizing cost-effectiveness through real-time imaging [3]. Group 2 - The intuitive software of the BD FACSDi scover™ A8 is designed for managing large datasets and is ready for standardized operation out of the box [3]. - The instruments can seamlessly integrate with the BD FACSDi scover™ S8 imaging spectral sorter and the BD reagent ecosystem, including the recently launched BD Horizon RealViolet™ 828 and RealBlue™ 824 fluorescent dyes, which are pioneering products in the near-infrared spectral range [3]. - Steve Conley, Global President of BD Biosciences, emphasized the importance of flexibility and modularity in acquiring cutting-edge technology in today's complex research environment, stating that the A8 series is rapidly adopted by leading biopharmaceutical companies and now offers more entry-level options for organizations of all sizes [3].

Group 1: Export Data Overview - November exports increased by 5.9% year-on-year, exceeding the expected 3% and recovering from a previous decline of -1.1% in October[7] - The rise in exports is attributed to the easing of supply disruptions rather than an improvement in external demand[2] - The number of working days in November increased by 2 days compared to the previous year, contributing to the export rebound[2] Group 2: Import Data Overview - November imports rose by 1.9% year-on-year, slightly below the expected 2.9% but up from 1% in October[7] - Processing trade imports surged by 9.2 percentage points to 13.9%, indicating a recovery in trade activity[26] - Major commodities like crude oil saw a rebound in import growth, with an increase of 8.4 percentage points to 8.1%[26] Group 3: Sector-Specific Insights - Consumer electronics exports grew by 5.1 percentage points to 3.3%, with significant contributions from mobile phones and LCD display modules[37] - Capital goods exports showed mixed results, with general machinery and medical instruments increasing, while shipbuilding exports fell significantly[43] - Exports to emerging markets, particularly Africa and Latin America, saw notable increases of 17.1 and 12.8 percentage points, reaching 27.7% and 15% respectively[14] Group 4: Future Outlook - The easing of supply disruptions and ongoing competitive advantages for Chinese exports are expected to support export growth in the coming months[30] - Potential improvements in exports to the U.S. are anticipated due to reduced tariffs and ongoing inventory replenishment needs[30] - Continued industrialization in emerging economies is likely to drive demand for intermediate and capital goods from China[30]

具有多个独立控温箱体的培养箱及人工智能温控系统 专利号：ZL 2025 1 1308221.X 日 前 ， 上 海 博 迅 医 疗 生 物 仪 器 股 份 有 限 公 司 （ 以 下 简 称 " 公 司 " ） 公 布 取 得 国 家 知 识 产 权 局 颁 发 的 3 项 《 发 明 专 利 证 书》，分别为： 恒温恒湿箱及人工智能控制系统 专利号：ZL 2025 1 1259332.6 基于深度强化学习的蒸汽灭菌器及智能控制系统 专利号：ZL 2025 1 1263335.7 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 发 文 不 易 ， 请 帮 小 编 点 下 " ❤️ " 上述专利证书的取得，有利于公司加强对知识产权的保护力度，进一步完善 知识产权保护体系，促进公司技术创新与 专业积累，不断提升自身的核心竞争力。 ↓ ↓ 加入行业讨论群 ↓ ↓ | 版 权 ： 本 文 部 分 素 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 A股上市公司联影医疗发布公告称 ， 公司五大员工持股平台合计减持股份1337万股 ， 总价值高达18.2亿元 。 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 具体来看这笔减持 —— 联影医疗的五家员工持股平台宁波影聚 、 宁波影力 、 宁波影健 、 宁波影康及上海影董 ， 通过集中竞价及大宗交易方式减持公司股份 ， 持股数量减少约1337万股 ， 总金额为18.2亿元 。 | 责 编 ： 安 安 公告显示 ， 联影医疗的员工持股计划已覆盖800余名受益人 ， 主体为在岗雇员及曾对公司做出突出贡献的人员 ， 合计持有员工持股计划6000万份 。 以此计算 ， 此次减持后 人均可落袋至少200万元 。 这些员工中不仅有董事长 、 总经理等高级管理人员 ， 还不乏核心技术人员等业务骨干 。 ↓ ↓ 加入行业讨论群 ↓ ↓ | 视 ...

Core Insights - 908 Devices Inc. (NASDAQ:MASS) is focused on handheld chemical analysis tools for health, safety, and defense applications, aiming to establish a more predictable and profitable business model through its 908 Devices 2.0 vision [1] Financial Performance - For Q3 2025, MASS reported an earnings per share (EPS) of -$0.41, missing the estimated EPS of -$0.11 and significantly below the Zacks Consensus Estimate of a $0.13 loss [2][6] - The company exceeded revenue expectations with $14 million in revenue, surpassing the estimated $13.5 million and the Zacks Consensus Estimate by 3.17%, although this represents a decline from $16.77 million reported a year ago [3][6] - MASS has a negative price-to-earnings (P/E) ratio of approximately -12.42, indicating current losses, while the price-to-sales ratio is about 3.81, suggesting investors are willing to pay $3.81 for every dollar of sales [4] - The enterprise value to sales ratio is approximately 2.87, providing insight into the company's valuation relative to its revenue [4] Financial Health - The company maintains a strong current ratio of approximately 4.98, indicating good short-term financial health and liquidity [5][6] - MASS has a low debt-to-equity ratio of about 0.03, showing minimal reliance on debt financing [5] - The enterprise value to operating cash flow ratio is negative at around -6.04, highlighting potential challenges in generating cash flow from operations [5]